Research programme: galectin modulators - Galecto Biotech

Drug Profile

Research programme: galectin modulators - Galecto Biotech

Alternative Names: Galectin activators - Galecto Biotech; Galectin inhibitors - Galecto Biotech; Galectin-3 inhibitors - Galecto Biotech

Latest Information Update: 05 Nov 2014

Price : $50

At a glance

  • Originator Galecto Biotech
  • Class Small molecules
  • Mechanism of Action Galectin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Fibrosis; Inflammation

Most Recent Events

  • 03 Nov 2014 Bristol Myers-Squibb gains exclusive option to acquire Galecto Biotech
  • 30 Jan 2014 Early research in Cancer in Sweden (unspecified route)
  • 30 Jan 2014 Early research in Inflammation in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top